Physician profile
Mitchell Reid Halper
NPI 1205039658
$11,840.31
in general payments reported to CMS, 2019-2025
18 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.15 · 2020: $439 · 2021: $1,558 · 2022: $2,361 · 2023: $4,744 · 2024: $2,185 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,850 · Food and Beverage: $1,450 · Travel and Lodging: $90.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,850.00 |
| Food and Beverage | $1,450.36 |
| Travel and Lodging | $90.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,201.28 | 2021-2025 | |
| Lundbeck LLC | $697.14 | 2020-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $420.93 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $287.13 | 2021-2025 | Ingrezza |
| Corium, LLC | $222.67 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $220.68 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $212.64 | 2020-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Allergan, INC. | $154.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $93.20 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $74.54 | 2021-2023 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $60.22 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $55.23 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $35.00 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.02 | 2025 | Cobenfy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $18.36 | 2020 | |
| Indivior INC. | $17.29 | 2019 | |
| Shire North American Group INC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Halper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.